Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
  1. No Image 01Jun
    by

    Yuhan ups investment in biotechs for immuno-oncology drug push

  2. No Image 01Jun
    by

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

  3. No Image 01Jun
    by

    Profiles of Four New Stock-Billionaires

  4. No Image 03Mar
    by

    Other news to note for March 2, 2021

  5. No Image 01Jun
    by

    Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

  6. No Image 01Jun
    by

    Oscotec`s acute leukemia treatment wins orphan drug status from FDA

  7. No Image 01Jun
    by

    Oscotec wins exception policy for continued R&D for new drugs

  8. No Image 01Jun
    by

    Oscotec shares rebound on launch of US clinical trial

  9. No Image 03Mar
    by

    Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

  10. No Image 01Jun
    by

    More than half of Korean biopharma firms view R&D investments as assets.

  11. No Image 01Jun
    by

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  12. No Image 01Jun
    by

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.